Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
The Eppendorf Tube 5.0 mL system, from Eppendorf North America, handles volumes up to 5 mL. The tubes feature a snap cap for single-hand operation and a compact conical design, removing the risk of contamination associated with manipulating small volumes in large tubes.
Beckman Coulter Life Sciences has acquired the flow cytometry business assets of ReaMetrix India, a Bangalore-based life science technology company. The transaction provides Beckman Coulter with temperature-stable, single-dose, multi-color antibody cocktails targeting the HIV monitoring and clinical research markets.
Mercy Medical Center in Canton, Ohio, has implemented advanced clinical laboratory diagnostic technology for conducting on-demand HbA1c diabetes testing, as well as analysis of red blood cell, white blood cell, and platelet counts. Mercy did this by installing Sysmex America’s XN-9000 Lavender Top Management configuration. As North America’s first installation of its kind, the Sysmex Lavender Top Management system, designed and manufactured by Bio-Rad Laboratories and Sysmex America, builds on Mercy’s Sysmex XN-9000 system and further optimizes lab workflow, staffing,
NorDx, a large reference laboratory in Maine that is a member of MaineHealth, has acquired Sysmex America’s XN-3000 automated hematology analyzers. The XN-3000 configuration enables enhanced diagnostic capabilities and greater efficiency that transforms NorDx into an accountable care laboratory model. The Sysmex XN-3000 has a menu of advanced clinical parameters that allows NorDx and MaineHealth to conduct cellular studies that enable the quantitative assessments of red cell, white cell, and platelet precursors, guiding diagnosis and treatment by the physician. These
Ontario-based Brockville General Hospital and Sysmex Canada announced the hospital’s installation and implementation of a Sysmex XN-2000 automated hematology analyzer. This is the first Sysmex XN series analyzer to be installed in Canada. The compact automated hematology analyzer provides the hospital’s clinical laboratory with expanded clinical and operational capabilities to meet changing workload demands and testing complexity that may accompany an aging population, while withstanding future medical technologist shortages. The Sysmex XN series suite of products includes the XN-1000, XN-2000,
Sysmex America recently introduced its Sysmex XP-300, an update for smaller labs in the U.S. and recently introduced to the Latin America and Caribbean market, as well as its Sysmex DI-60 integrated slide processing system, which provides seamless integration of automated slide making/staining and digital cell image classification. The Sysmex XP-300 automated hematology analyzer is part of the company’s three-part differential analyzer portfolio and combines the reliability and heritage of the KX-21N with updated, user-friendly software. The XP-300 has a
EKF Diagnostics offers a novel test to accurately identify diabetic patients at high risk of progression to end-stage renal disease (ESRD) up to 10 years before currently available tests can. EKF’s sTNFr1 test is an ELISA assay that has the potential to significantly improve diabetic patient management and outcomes. The test accurately detects circulating levels of soluble tumor necrosis factor receptor 1 (sTNFr1) in patient samples. Research has demonstrated that high circulating levels of sTNFr1 are strongly associated with progression
EKF Diagnostics offers its Stat-Site M Hgb strip-based test for quick and easy hemoglobin analysis for rapid anemia determination. Stat-Site M Hgb is a portable handheld analyzer. The pocket-sized device delivers accurate hemoglobin analysis results within 30 seconds from 15 µL of fingerstick whole blood. This hemoglobin photometer is maintenance-free and includes intuitive, step-by-step on-screen instructions to minimize operator training. Its durability, portability, and user-friendliness make the device especially suited to blood screening programs in developing world markets. It also
EKF Diagnostics’ Stat-Site M β-HB is a strip-based test for β-hydroxybutyrate that provides a quick and easy assessment of diabetic ketoacidosis (DKA), delivering results in less than 80 seconds. The presence and degree of ketosis can be assessed rapidly at the point of care by accurately measuring blood levels of β-HB, which accounts for 78 percent of the three ketone bodies, from 10 µL of serum or plasma. This results in useful information to provide quality care when monitoring DKA
EKF Diagnostics offers its EKF Molecular Diagnostics’ PointMan DNA enrichment kits. The three kits are for enriching mutations in BRAF, KRAS, and EGFR T790M genes associated with skin melanoma and colorectal and lung cancers. PointMan kits provide highly specific and ultrasensitive enrichment of mutant genes in a background of wild-type (normal) genes. PointMan real-time PCR technology provides reliable and extremely sensitive detection for cancer mutations. The technology is highly efficient at amplifying the target sequence of interest, while suppressing amplification
